

## **Longitudinal Characterization of the Tumoral Microbiome during Radiotherapy in HPV-associated Oropharynx Cancer**

*Houda Bahig<sup>1,2</sup>, Clifton D Fuller<sup>1</sup>, Aparna Mitra<sup>1</sup>, Travis Solley<sup>1</sup>, Sweet Ping Ng<sup>3</sup>, Ibrahim Abu-Gheida<sup>4</sup>, Baher Elgohari<sup>1,5</sup>, Andrea Delgado<sup>1</sup>, David I Rosenthal<sup>1</sup>, Adam S Garden<sup>1</sup>, Steven J Frank<sup>1</sup>, Jay P Reddy<sup>1</sup>, Lauren Colbert<sup>1</sup>, Ann Klopp<sup>1</sup>*

<sup>1</sup>*Radiation Oncology Department, University of Texas MD Anderson Cancer Center, Houston, Texas, USA*

<sup>2</sup>*Radiation Oncology Department, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada*

<sup>3</sup>*Radiation Oncology Department, Peter MacCallum Cancer Centre, Melbourne, Australia*

<sup>4</sup>*Radiation Oncology Department, Burjeel Medical City, Abu-Dhabi, United Arab Emirates*

<sup>5</sup>*Clinical Oncology and Nuclear Medicine Department, Mansoura University, Mansoura, Egypt*

### **Corresponding author:**

Houda Bahig, MD PhD  
Centre Hospitalier de l'Université de Montréal/MD Anderson Cancer Center  
1051 Sanguinet Street,  
Montreal, Quebec. H2X 3E4 Canada  
514-690-8546  
[Houda.bahig.chum@ssss.gouv.qc.ca](mailto:Houda.bahig.chum@ssss.gouv.qc.ca)

**Short running title:** Tumor microbiome in HPV + oropharynx cancer

**Conflict of interest:** None

**Funding:** This work was supported by generous philanthropic contributions to the University of Texas MD Anderson HPV-Related Cancers Moon Shot Program.

## ABSTRACT

**Purpose:** To describe the baseline and serial tumor microbiome in HPV-associated oropharynx cancer (OPC) over the course of radiotherapy (RT).

**Methods:** Patients with newly diagnosed HPV-associated OPC treated with definitive radiotherapy +/- concurrent chemotherapy were enrolled in this prospective study. Using 16S rRNA gene sequencing, dynamic changes in tumor microbiome during RT were investigated. Surface tumor samples were obtained before RT and at week 1, 3 and 5 of RT. Radiological primary tumor response at mid-treatment was categorized as complete (CR) or partial (PR).

**Results:** Ten patients were enrolled. Mean age was 63 years (range: 51-71). As per AJCC 8<sup>th</sup> Ed, 50%, 20% and 30% of patients had stage I, II and III, respectively. At 4-weeks, 7 patients had CR and 3 patients had PR; at follow-up imaging post treatment, all patients had CR. Baseline diversity of tumoral and buccal microbiomes was not statistically different. For the entire cohort, alpha diversity was significantly decreased over the course of treatment ( $p=0.02$ ). There was a significant alteration in the bacterial community within the first week of radiation. Baseline tumor alpha diversity of patients with CR was significantly higher than those with PR ( $p=0.03$ ). While patients with CR had significant reduction in diversity over the course of radiation ( $p=0.02$ ), the diversity remained unchanged in patients with PR. Patients with history of smoking had significantly increased abundance of *Granulicatella* ( $p=0.04$ ), and *Kingella* (0.05) and lower abundance of *Alloprevotella* ( $p=0.04$ ) compared to never smokers.

**Conclusions:** The tumor microbiome of HPV-associated OPC exhibits reduced alpha diversity and altered taxa abundance over the course of radiotherapy. The baseline bacterial profiles of smokers vs. non-smokers were inherently different. Baseline tumor alpha diversity of patients with CR was higher than patients with PR, suggesting that the microbiome as a biomarker of radiation response deserves further investigation.

## 1. INTRODUCTION

The last decades have seen the emergence of human papillomavirus (HPV) –associated squamous cell carcinoma of the oropharynx cancer (OPC), that now constitutes the vast majority of OPC in North America (1, 2). HPV-associated OPC has a significantly improved prognosis compared to non-HPV-associated OPC (3, 4), and is currently the focus of multiple trials of treatment de-intensification, in an attempt to reduce treatment-

related morbidity (5-10). However, it is now recognized that a subset of HPV-associated OPC presents with highly aggressive behaviour and may not be suited for these treatment de-intensification approaches that may result in jeopardized patients outcomes (11). This poor prognosis subgroup remains poorly defined and reliable patient-specific biomarkers that can predict treatment response are greatly needed. Complete response at mid-treatment is observed in as high as 50% of patients with HPV-associated OPC (12), and tumor response to radiotherapy has been shown to be associated with permanent tumor control outcomes (13).

Across multiple cancer sites, cumulating evidence suggests that the microbiome could impact cancer risk and treatment outcomes (14-19). More specifically, the oral microbiome hosts several hundred bacterial species and is emerging as a new potential biomarker reservoir for head and neck cancers (20, 21). Differences in composition between the oral microbiome of patients with oral cavity and oropharynx cancers and that of healthy individuals have lead to recent initiatives investigating the potential role of the oral microbiome for early detection of head and neck malignancies (22, 23). Previous studies have shown that the composition of the oral microbiome was altered over the course of radiotherapy in oral cavity cancer (24, 25). To our knowledge, there is currently no study characterizing the tumor microbiome in OPC treated with radiotherapy.

The aim of this pilot study is two-fold: (1) to describe the baseline and longitudinal changes in tumor microbiome in HPV-associated OPC over the course of radiotherapy (RT); (2) to compare the tumor microbiome of early vs. late radiotherapy responders. In

doing so, we hope to generate hypothesis that would lay ground for future larger scale work on the role of tumor microbiome in predicting treatment response.

## **2. MATERIAL AND METHODS**

### **2.1 Patients**

Patients with newly diagnosed HPV-associated squamous cell carcinoma of the oropharynx treated with radical radiotherapy +/- cisplatin-based chemotherapy and whose tumour could be accessed by surface swab in the clinic were prospectively enrolled. Patients treated with induction chemotherapy or robotic surgery, and patients with previous head and neck malignancy were excluded. Patients were treated with standard of care radiotherapy at a dose of 70 Gy in 33 fractions over 6-7 weeks. This study was approved by our institutional ethics committee (MDACC 2014-0543), and all patients signed a consent form.

### **2.2 Response Assessment**

All patients underwent pre-treatment planning computed tomography (CT) and, unless contra-indicated, a planning magnetic resonance imaging (MRI) of the head and neck region. In addition, all patients underwent mid-treatment (week 4) repeat planning CT and MRI for early primary tumor response assessment. Mid-treatment primary tumor response was classified as complete (CR), partial (PR) or stable (SD), based on RECIST criteria version 1.1.. A contrast-enhanced CT of the head and neck was obtained at 8 weeks after treatment completion for definitive treatment response assessment. In cases where response at 8 weeks post treatment was incomplete, a fluorodeoxyglucose (FDG)-

positron emission tomography/ computed tomography (PET/CT) was obtained at 12 weeks after RT completion for further assessment of response.

### **2.3 Microbiome sample collection and analysis**

Tumor microbiome samples were obtained immediately before RT start and at week 1, 3 and 5 using a matrix designed quick release Isohelix swab (DSK-50 and XME-50, isohelix.com, UK). Samples were obtained by brushing the swab against the viable tumor several times in order to collect enough cells from the tumor surface. At baseline (i.e. immediately before RT start), an oral microbiome swab was also obtained by brushing the swab against healthy buccal mucosa, to serve as control. Isohelix swabs were placed in 20  $\mu$ L of protease K and 400  $\mu$ L of lysis buffer (Isohelix) and stored at  $-80^{\circ}\text{C}$  within 1 h of sample collection. Bacterial genomic DNA was extracted using MO BIO PowerSoil DNA Isolation Kit (MO BIO Laboratories). Microorganism identification derived from culture-based approaches, using the 16 Svedberg unit (S) rRNA gene technology for bacteria. 16S rRNA gene sequencing was performed by the Alkek Center for Metagenomics and Microbiome Research at Baylor College of Medicine. 16S rRNA was sequenced methods previously detailed in the Human Microbiome Project (26). Shannon diversity index was used to evaluate alpha (within sample) diversity. Relative abundance of the microbiome taxa and genera was compared between patients presenting CR vs. PR/SD at mid-treatment. Using the Kruskal-Wallis test, an  $\alpha$  of  $\leq 0.05$  was considered significant.

## **3. RESULTS**

### 3.1 Patients characteristics

Ten patients were enrolled. Mean age was 63 years (range: 51-71) and all patients were male (**Table 1**). Tumor was located in the tonsil and in the base of tongue in 60% and 40% of patients, respectively. As per AJCC 8<sup>th</sup> Ed, 50%, 20% and 30% of patients had stage I, II and III, respectively. 40% were smokers (active or past), while 60% never smoked. All patients were treated to a dose of 70 Gy in 33-35 fractions. Eight patients underwent concurrent platin-based chemotherapy that consisted in weekly cisplatin at 40 mg/m<sup>2</sup>, and one patient received Nivolumab every 14 days for 10 doses starting 14 days prior to IMRT. At 4-weeks, 7 patients had CR and 3 patients had PR. At 8 weeks post treatment, all patients with CR at mid treatment had persistent CR, while among patients with mid-treatment PR, 1 had CR and 2 had persistent PR at the primary site and/or lymph nodes. All patients had complete response on PET/CT at 12 weeks post-treatment. Six patients were treated with volumetric arc therapy while 4 patients were treated with intensity modulated proton therapy.

**Table 1. Patients Characteristics**

<b>Age (y; median)</b>		63 (51-71)
<b>Gender (N)</b>	<b>Male</b>	10
<b>Tumor subsite (N)</b>	<b>Tonsil</b>	6
	<b>Base of tongue</b>	4
<b>Stage (AJCC 8th Ed; N)</b>	<b>I</b>	5
	<b>II</b>	2
	<b>III</b>	3
<b>Smoking status (N)</b>	<b>Smokers (past or active)</b>	4

	Never smokers	6
<b>Treatment (N)</b>		
	<b>Chemo-RT</b>	8
	<b>RT alone</b>	2

### 3.2 Characterisation of the mucosal microbiome

Baseline alpha diversity of tumoral and buccal microbiomes was not statistically different (**Figure 1**). Baseline alpha diversity of patients who had a CR by 4 weeks was significantly higher than those who had a PR ( $p=0.03$ ) (**Figure 2**). For the entire cohort, alpha diversity was significantly decreased over the course of treatment ( $p=0.02$ ) (**Figure 3**). However, patients with CR at 4-weeks had significantly reduced alpha diversity over the course of radiation ( $p=0.02$ ), while diversity remained unchanged in patients with PR. Patients with history of smoking had significantly increased abundance of *Granulicatella* ( $p=0.04$ ), and *Kingella* (0.05) and lower abundance of *Alloprevotella* ( $p=0.04$ ) compared to never smokers (**Figure 4**). There was a shift in the composition of the bacterial community over the course of radiation. The relative composition of Actinomyces declined over the course of radiation. Other organisms, such as *Gemella* and *Streptococcus*, decreased in abundance between baseline and week 1 and subsequently returned to baseline abundance by week 5. (**Figure 5**). This was followed by progressive re-normalization on subsequent weeks.

## 4. DISCUSSION

This is the first study characterizing the tumor microbiome in HPV-associated OPC and exploring its role in the prediction of response to radiotherapy. In this pilot study, we



report that the alpha diversity was significantly reduced over the course of treatment and that the composition of the microbiota was rapidly altered as early as in the first week of radiation. The baseline alpha diversity of the tumor microbiome was significantly higher in rapid responders (i.e. those with complete response at mid-treatment). We found that the tumor microbiome profiles of smokers vs. non-smokers were significantly different.

The oral microbiome has been hypothesised to play a role in the pathogenesis of head and neck cancers, through chronic inflammation, anti-apoptotic cellular signalling and release of carcinogens (27). In fact, inherent differences in the bacterial flora of healthy individuals versus individuals with oral cavity/oropharynx cancers have been documented in several studies, and various mechanisms supporting a carcinogenic role of the oral microbiome have been postulated (28-33). As an example, acetaldehyde, a toxic ethanol metabolite produced via bacterial oxidation is found in higher concentration in heavy alcohol users with poor oral hygiene and its accumulation has been linked to increased risk of oral cavity cancer (34, 35). Similarly, a synergistic effect of periodontitis - a chronic infection caused by gram-negative anaerobic bacteria- and oral HPV co-infection has been suggested for the development of OPC cancer, as the continuous release of bacterial toxins and inflammatory markers in the oral cavity would enhance epithelial tissue abrasion, basal cells infection, and ultimately persistence of HPV infection (36). The role of the oral microbiome to predict the therapeutic efficacy of radiotherapy in patients with head and neck cancers has never previously been investigated. Nonetheless, consistent with the results of the present study, our group has previously shown that an increased diversity of the vaginal microbiome was also associated with enhanced response to radiotherapy in HPV-associated cervical cancer

(37). In addition, numerous recent studies have focused on the role the gut microbiome as a modulator of the response to immune checkpoint inhibitors in several cancers, including melanoma, lung and renal cancer (14-19). In these studies, an increased alpha diversity of the microbiome was associated with higher therapeutic efficacy of immune checkpoint inhibitors (14, 19). However, in Checkmate 141, a trial investigating the role of Nivolumab in recurrent or metastatic head and neck cancer, the oral microbiome and its alpha diversity were not predictive of the therapeutic response to immunotherapy (38). A study at the Princess Margaret Cancer Centre (NCT034106615) assessing oral and intestinal microbiota in patients with head and neck cancer treated with radical chemoradiotherapy is currently on-going.

The dynamic variation of the oral microbiome over the course of head and neck radiotherapy has not been well studied. Huo et al, correlated the dynamic oral microbiome change with the severity of mucositis in patients treated for nasopharynx cancer and found that, although the bacterial alpha diversity did not vary significantly over treatment, there were synchronous shifts in the abundance of specific bacteria such as Prevotella, Fusobacterium, Treponema and Porphyromonas (25). Similarly, Zhu et al. showed that the microbiome profile of patients undergoing radiotherapy for nasopharynx cancer was progressively altered during radiation therapy, in close correlation with development of mucositis (24, 25).

Our study reports preliminary outcomes from an on-going initiative assessing the role of the microbiome in HPV-associated cancers. Given the small sample size, the results of this report, while hypothesis generating, are not definitive. Further work is required to

further understand and determine if the tumor microbiome truly has a role in the prediction of therapeutic efficacy in head and neck cancers. In addition, distinctions between the dynamic alterations of the microbiome of patients treated with radiotherapy alone vs. concurrent chemoradiation could not be effectively studied. Another limitation is the lack of concurrent gut microbiome data; however, the role of the gut microbiome may not have the same importance in the context of head and neck radiotherapy as compared to systemic therapy, given that the main anti-tumor mechanisms are local. Finally, an inherent limitation of studies assessing the role of the microbiome is the regional microbiome variations, which may limit the external validity of study findings and warrant local confirmatory investigations.

In conclusion, we found that the tumor microbiome of our entire cohort of patients with HPV-associated OPC exhibits reduced alpha diversity over the course of radiation. This was also associated with an altered taxa abundance manifesting as early as in the first week of radiotherapy. Although not definitive, we found that baseline alpha diversity of patients with complete response by mid-treatment was higher than patients with partial responses or stable disease. While the diversity of the tumor microbiome as a biomarker of radiation response in OPC deserves further investigation, these preliminary outcomes are encouraging and lay ground for further work in that direction.

## **REFERENCES**

1. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. *Lancet Oncol.* 2010;11(8):781-9.
2. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? *Cancer.* 2007;110(7):1429-35.
3. Ang KK, Sturgis EM. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. *Seminars in radiation oncology.* 2012;22(2):128-42.
4. Garden AS, Kies MS, Morrison WH, Weber RS, Frank SJ, Glisson BS, et al. Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. *Radiat Oncol.* 2013;8:21.
5. Kofler B, Laban S, Busch CJ, Lorincz B, Knecht R. New treatment strategies for HPV-positive head and neck cancer. *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery.* 2014;271(7):1861-7.
6. Masterson L, Moualed D, Liu ZW, Howard JE, Dwivedi RC, Tysome JR, et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. *European journal of cancer (Oxford, England : 1990).* 2014;50(15):2636-48.
7. Hay A, Ganly I. Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy. *Rare Cancers Ther.* 2015;3:89-117.
8. Lee N, Schoder H, Beattie B, Lanning R, Riaz N, McBride S, et al. Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma. *International journal of radiation oncology, biology, physics.* 2016;96(1):9-17.
9. Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, et al. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx-ECOG-ACRIN Cancer Research Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2017;35(5):490-7.
10. Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. *The Lancet Oncology.* 2017;18(6):803-11.
11. Azeem S, Kaka BK, Pawan Kumar, Paul E, Wakely, Claudia M, Kirsch, MD, de Matthew O, Old, Enver Ozer, Amit Agrawal, Ricardo E. Carrau, David E. Schuller, Farzan Siddiqui and Theodoros N. Teknos. Highly Aggressive HPV-related Oropharyngeal Cancer: Clinical, Radiologic, and Pathologic Characteristics. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2013 Sep; 116(3): 327–335 2013.
12. Ding Y, Hazle JD, Mohamed AS, Frank SJ, Hobbs BP, Colen RR, et al. Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. *NMR Biomed.* 2015;28(12):1645-54.
13. Bataini JP, Jaulerry C, Brunin F, Ponvert D, Ghossein NA. Significance and therapeutic implications of tumor regression following radiotherapy in patients treated for squamous cell carcinoma of the oropharynx and pharyngolarynx. *Head Neck.* 1990;12(1):41-9.
14. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science.* 2018;359(6371):91-7.

15. Santoni M, Piva F, Conti A, Santoni A, Cimadamore A, Scarpelli M, et al. Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors. *Eur Urol*. 2018;74(4):521-2.
16. Mitsuhashi A, Okuma Y. Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. *Clin Transl Oncol*. 2018;20(8):966-74.
17. Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. The microbiome of the urinary tract--a role beyond infection. *Nat Rev Urol*. 2015;12(2):81-90.
18. Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, et al. Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients. *Neoplasia*. 2017;19(10):848-55.
19. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science*. 2018;359(6371):97-103.
20. Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner AC, Yu WH, et al. The human oral microbiome. *Journal of bacteriology*. 2010;192(19):5002-17.
21. Lim Y, Totsika M, Morrison M, Punyadeera C. The saliva microbiome profiles are minimally affected by collection method or DNA extraction protocols. *Scientific reports*. 2017;7(1):8523.
22. Mager DL, Haffajee AD, Devlin PM, Norris CM, Posner MR, Goodson JM. The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. *Journal of translational medicine*. 2005;3:27.
23. Bolz J, Dosa E, Schubert J, Eckert AW. Bacterial colonization of microbial biofilms in oral squamous cell carcinoma. *Clinical oral investigations*. 2014;18(2):409-14.
24. Hu YJ, Wang Q, Jiang YT, Ma R, Xia WW, Tang ZS, et al. Characterization of oral bacterial diversity of irradiated patients by high-throughput sequencing. *Int J Oral Sci*. 2013;5(1):21-5.
25. Zhu XX, Yang XJ, Chao YL, Zheng HM, Sheng HF, Liu HY, et al. The Potential Effect of Oral Microbiota in the Prediction of Mucositis During Radiotherapy for Nasopharyngeal Carcinoma. *EBioMedicine*. 2017;18:23-31.
26. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. *Nature*. 2007;449(7164):804-10.
27. Vogelmann R, Amieva MR. The role of bacterial pathogens in cancer. *Curr Opin Microbiol*. 2007;10(1):76-81.
28. Schmidt BL, Kuczynski J, Bhattacharya A, Huey B, Corby PM, Queiroz EL, et al. Changes in abundance of oral microbiota associated with oral cancer. *PloS one*. 2014;9(6):e98741.
29. Wu J, Peters BA, Dominianni C, Zhang Y, Pei Z, Yang L, et al. Cigarette smoking and the oral microbiome in a large study of American adults. *The ISME journal*. 2016;10(10):2435-46.
30. Wolf A, Moissl-Eichinger C, Perras A, Koskinen K, Tomazic PV, Thurnher D. The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study. *Scientific reports*. 2017;7(1):5867.
31. Schmidt BL, Kuczynski J, Bhattacharya A, Huey B, Corby PM, Queiroz EL, et al. Changes in abundance of oral microbiota associated with oral cancer. *PloS one*. 2014;9(6):e98741.
32. Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, Rodriguez-Hilario A, Gonzalez H, Bondy J, et al. 16S rRNA amplicon sequencing identifies microbiota associated with oral

cancer, human papilloma virus infection and surgical treatment. *Oncotarget*. 2016;7(32):51320-34.

33. Pushalkar S, Ji X, Li Y, Estilo C, Yegnanarayana R, Singh B, et al. Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. *BMC Microbiol*. 2012;12:144.

34. Homann N, Tillonen J, Meurman JH, Rintamaki H, Lindqvist C, Rautio M, et al. Increased salivary acetaldehyde levels in heavy drinkers and smokers: a microbiological approach to oral cavity cancer. *Carcinogenesis*. 2000;21(4):663-8.

35. Salaspuro V, Salaspuro M. Synergistic effect of alcohol drinking and smoking on in vivo acetaldehyde concentration in saliva. *Int J Cancer*. 2004;111(4):480-3.

36. Tezal M, Sullivan Nasca M, Stoler DL, Melendy T, Hyland A, Smaldino PJ, et al. Chronic periodontitis-human papillomavirus synergy in base of tongue cancers. *Arch Otolaryngol Head Neck Surg*. 2009;135(4):391-6.

37. (ABSTRACT). Association of changes in vaginal microbiome with oligoclonal T-cell expansion and early response to chemoradiation for cervical cancer. *JCO*. Lauren Elizabeth Colbert, Andrea Delgado Medrano, Rebecca A. Previs, Patricia J. Eifel, Anuja Jhingran, Lois M. Ramondetta, Phillip Andrew Futreal, Amir A. Jazaeri, Robert Tyler Hillman, Michael M. Frumovitz, Kathleen M. Schmeler, Megan Mikkelsen, Geena Mathew, Nadim Ajami, Pablo Okhuysen, Joseph Petrosino, Stephen M. Hahn, Ann Klopp.

38. Ferris RL BG, Harrington K, Fayette J, Guigay J, Colevas AD, et al. . (ABSTRACT) Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141. *Cancer Res Cancer Res* 2017;77(13 Suppl)(CT022.).

**Table 1. Patients Characteristics**

<b>Age (y; median)</b>		63 (51-71)
<b>Gender (N)</b>	<b>Male</b>	10
<b>Tumor subsite (N)</b>	<b>Tonsil</b>	6
	<b>Base of tongue</b>	4
<b>Stage (AJCC 8th Ed; N)</b>	<b>I</b>	5
	<b>II</b>	2
	<b>III</b>	3
<b>Smoking status (N)</b>	<b>Smokers (past or active)</b>	4
	<b>Never smokers</b>	6
<b>Treatment (N)</b>	<b>Chemo-RT</b>	8
	<b>RT alone</b>	2

**Figure 1. Baseline alpha diversity of tumoral and buccal microbiomes**




**Figure 2. Baseline alpha diversity of patients with CR vs. PR at mid-treatment**


### **Figure 3. Changes in alpha diversity over the course of treatment**

**Figure 4. Comparison of the microbial composition of smokers vs. never smokers**

**Figure 5. Dynamic alteration in taxa abundance over the course of radiation. The relative abundance of organisms at the genus level at baseline and throughout the course of chemoradiation are shown.**




Diversity Metric	Time in weeks	Statistic	P-Value	FDR-Adj. P
Observed OTUs	0	Mann-Whitney	0.000469231761049	0.000469231761049
Shannon	0	Mann-Whitney	0.17281410390585	0.17281410390585
InvSimpson	0	Mann-Whitney	0.315419009534257	0.315419009534257




\* Mid treatment primary tumor response

CR  
PR

Diversity Metric	Time in weeks	Statistic	P-Value
Shannon	0	Mann-Whitney	0.0333333333333333
Shannon	1	Mann-Whitney	0.183333333333333
Shannon	3	Mann-Whitney	0.5
Shannon	5	Mann-Whitney	0.380952380952381



Metric	Mid treatment primary tumor response	P-Value
Shannon	CR	0.000609291024715609
Shannon	PR	0.3480563688732117
InvSimpson	CR	0.00336818177560943
InvSimpson	PR	0.650390777479065



Taxa	Statistic	P-Value
Granulicatella	Mann-Whitney	0.03809523680952381
Alloprevotella	Mann-Whitney	0.042196956949785
Kingella	Mann-Whitney	0.0546539308916751
Leptotrichia	Mann-Whitney	0.0666666666666667
Fusobacterium	Mann-Whitney	0.114285714285714
Prevotella	Mann-Whitney	0.134405759215731
Tannerella	Mann-Whitney	0.149101216651651

smoking status




Never smokers



Smokers





Taxa	Statistic	P-Value	FDR-Adj. P	Overall Mean	Mean of 0	Mean of 1	Mean of 3	Mean of 5
Actinomyces	Kruskal-Wallis	0.0120087375687323	0.176696151385208	1.12	1.42	1.7	0.69	0.5
Leptotrichia	Kruskal-Wallis	0.0137584126870241	0.176696151385208	3.18	3.67	4.9	3.14	0.75
Streptococcus	Kruskal-Wallis	0.0218150239370416	0.176696151385208	18.22	26.68	3.89	18.99	26.94
Scorotibacterium	Kruskal-Wallis	0.0203852084650813	0.176696151385208	0.29	0.23	0.64	0.17	0.06
Leptotrichia	Kruskal-Wallis	0.0313250481047088	0.176696151385208	0.42	1.42	0	0	0.15
Gemella	Kruskal-Wallis	0.055578244272186	0.176696151385208	2	1.07	0.15	1.34	5.7
Actinophila	Kruskal-Wallis	0.0681404417867702	0.27539158803002	0.09	0.3	0	0.01	0.03